CLVTCLARIVATE PLC

NYSE clarivate.com


$ 5.93 $ -0.08 (-1.33 %)    

Monday, 20-May-2024 15:59:59 EDT
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 5.93
$ 6.01
$ 0.00 x 0
$ 0.00 x 0
$ 5.84 - $ 6.01
$ 5.85 - $ 10.03
9,690,629
na
3.96B
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 10-28-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 05-04-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-clarivate-stock-trading-higher-premarket-monday

Clarivate Plc launched AI-enhanced Trademark Watch Analyzer at 2024 International Trademark Association Annual Meeting, connect...

 clarivate-debuts-ai-enhanced-solution-to-accelerate-trademark-watching-at-inta-2024

Providing faster and more accurate answers to critical business questions LONDON, May 20, 2024 /PRNewswire/ -- Clarivate Plc (...

 goldman-sachs-maintains-buy-on-clarivate-lowers-price-target-to-75

Goldman Sachs analyst George Tong maintains Clarivate (NYSE:CLVT) with a Buy and lowers the price target from $8.5 to $7.5.

 clarivate-q1-2024-gaap-eps-014-inline-sales-621200m-beat-614860m-estimate

Clarivate (NYSE:CLVT) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 22.22 ...

 clarivate-unveils-epidemiology-intelligence-for-precision-patient-population-analysis

Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for p...

 clarivate-enhances-cortellis-cmc-intelligence-with-post-approval-module-to-accelerate-regulatory-success

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly en...

 clarivate-joins-united-nations-sustainable-development-goals-un-sdgs-publishers-compact

 Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United ...

 analytics-firm-clarivate-acquires-ai-start-up-motionhall---whats-on-the-cards

Clarivate has agreed to acquire the majority of assets of MotionHall, a Silicon Valley technology start-up. MotionHall serves l...

 exor-amplifies-stake-in-clarivate-proposes-new-board-member

Exor N.V. increases stake in Clarivate Plc to 10.1%, with potential to reach 17.5%. Suzanne Heywood to join board, showing stro...

 morgan-stanley-maintains-equal-weight-on-clarivate-lowers-price-target-to-8

Morgan Stanley analyst Toni Kaplan maintains Clarivate (NYSE:CLVT) with a Equal-Weight and lowers the price target from $9 t...

 barclays-maintains-underweight-on-clarivate-lowers-price-target-to-6

Barclays analyst Manav Patnaik maintains Clarivate (NYSE:CLVT) with a Underweight and lowers the price target from $7 to $6.

 rbc-capital-maintains-sector-perform-on-clarivate-lowers-price-target-to-8

RBC Capital analyst Ashish Sabadra maintains Clarivate (NYSE:CLVT) with a Sector Perform and lowers the price target from $1...

 oppenheimer-maintains-outperform-on-clarivate-lowers-price-target-to-10

Oppenheimer analyst Owen Lau maintains Clarivate (NYSE:CLVT) with a Outperform and lowers the price target from $11 to $10.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION